In vivo CAR-T therapies are an emerging approach with the potential to reshape autoimmune disease treatment if key scientific and clinical milestones are achieved. This executive summary explores early innovations, the significant scientific and regulatory complexities, and the steps needed to responsibly translate early promise into long-term patient impact.
Gain exclusive perspectives and practical insights to help you:
- Understand how in vivo CAR-T differs from traditional ex vivo approaches
- Navigate the safety, scalability, and early regulatory complexities of this emerging model
- Assess which regions are optimal for conducting autoimmune clinical trials
- Address manufacturing and operational hurdles with smarter design
- Prepare for commercialization and long-term readiness as the field evolves